This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Methadone and prolongation of QT interval

Authoring team

  • there is a risk of QT interval prolongation in patients taking methadone, especially those on high doses (1)
    • there is evidence that very-high-dose methadone may be associated with torsade de pointes (2)
  • recommended that patients with the following risk factors for QT interval prolongation are carefully monitored whilst taking methadone:
    • heart or liver disease, electrolyte abnormalities, concomitant treatment with CYP 3A4 inhibitors, or medicines with the potential to cause QT interval prolongation (1)
      • also any patient requiring more than 100mg of methadone per day should be closely monitored (1)
      • the RCGP guidance also notes that the risk of QT-interval prolongation may be dose-dependent (3)
        • "..methadone may be a risk factor for QT prolongation and torsade de pointes with a possible dose-dependent action... recommends monitoring for patients on high dose methadone (>100 mg daily) and with other QT interval prolongation risk factors where appropriate.."

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.